Ask. Wonder. Discover!

Korglutide is an oral 7-amino acid peptide dual agonist of GLP-1R and IGF-1R. Because it is a non-systemic peptide metabolized mainly by gastrointestinal peptidases rather than hepatic cytochrome P450 enzymes, it shows minimal risk of pharmacokinetic drug- drug interactions.

Alcohol or caffeine have no direct pharmacologic interactions but may reduce overall compliance or affect appetite modulation.

Korglutide is fundamentally different in structure and formulation:

- Short 7-amino-acid peptide: it has a compact, highly stable sequence that resists acid hydrolysis and enzymatic cleavage in the stomach.

- pH-stable formulation: it is formulated with excipients that protect the peptide from gastric degradation and allow it to transit into the small intestine.

No homology to GLP-1 analogs: because it is not a GLP-1 mimic but a dual GLP-1R and IGF-1R agonist, its molecular behavior and stability profile are distinct from conventional incretin peptides.

Korglutide appears to be safe in children; however, clinical data in this population remain limited, and further studies are needed to confirm its safety and efficacy.

Korglutide does not exhibit the typical gastrointestinal side effects commonly associated with GLP-1 agonists. Its unique mechanism and peptide structure provide a safer and more tolerable profile. Significantly fewer GI side effects have been observed (such as nausea, vomiting, and bloating) with minimal incidence compared to the high (30 - 50%) rate seen with GLP-1 agonists.